Companies in the UK are reportedly profiting by promoting misleading claims that collecting stem cells from children’s milk teeth can serve as a treatment for conditions such as diabetes and autism. An investigation led by Emma Wilkinson and published in the BMJ has highlighted the practices of three firms—BioEden, Future Health Biobank, and Stem Protect—which offer tooth stem cell banking services, costing approximately £1,900 with an annual storage fee of £95.
Tooth stem cell banking involves parents sending lost milk teeth to a laboratory where stem cells are harvested from the dental pulp. The companies claim these stem cells can potentially treat various medical conditions. For example, Future Health Biobank asserts on its website that it has released 26 tooth stem cell samples for treatments, including those for autism and type 1 diabetes. Similarly, Stem Protect claims that tooth stem cells can aid in repairing cleft palates and even address HIV/AIDS, suggesting that research into conditions like autism and cerebral palsy is ongoing.
Despite these claims, experts have raised significant concerns regarding the validity of such treatments. Jill Shepherd, a senior lecturer in stem cell biology at the University of Kent, noted, “There is a lack of evidence and a paucity of research using dental pulp stem cells to treat patients.” Shepherd emphasized that there is no credible evidence to indicate that stem cells stored from a child’s milk tooth would be necessary for treating that child.
The ethical implications of these marketing strategies are also under scrutiny. Sufyan Hussain, who is involved in a global clinical trial assessing stem cell therapy, highlighted the emotional nature of the issue, stating, “Parents naturally want the best possible outcomes for their children.” He cautioned that while there is hope for future treatments, the potential for companies to exploit parental concerns for profit remains a risk.
Additionally, Tim Nicholls, assistant director of policy, research and strategy at the National Autistic Society, criticized the marketing tactics of these firms. He stated, “It is outrageous that tooth stem cell procedures are being advertised to parents with the claim of ‘treating’ autism. Autism is not a disease or illness; it cannot be treated, and there is no cure.” Nicholls described the targeting of vulnerable families with such claims as “dangerous and morally bankrupt.”
In response to the findings published in the BMJ, Future Health Biobank stated it is reviewing how information is presented on its website to ensure clarity between client experiences and formally published clinical outcomes. A spokesperson for Stem Protect defended its practices, asserting that the company has made no unfounded claims and that its website has received approval from the Human Tissue Authority. They emphasized their commitment to transparency and evidence-based practices in stem cell banking.
The investigation underscores the importance of critical scrutiny when it comes to health-related claims and the need for parents to seek reliable information before making decisions regarding their children’s health.
